Mechanistic target of rapamycin inhibitors in solid organ transplantation
Authors:
- Maxime TouzotMTMaxime Touzot
- Jean Paul SoulillouJSJean Paul Soulillou
- Jacques DantalJDJacques Dantal
- 1 December 2012
- journal article
- review article
- Published by Wolters Kluwer Health in Current Opinion in Organ Transplantation
- Vol. 17 (6) , 626-633
Abstract
Here, we review recent advances and new insights in mechanistic target of rapamycin (mTOR) biology (signalling pathway, kidney biology and immune system), and recent clinical data on mTOR inhibitors related to solid organ transplantation. The mTOR pathway is a major integrator of signals governing protein and lipid biosynthesis and growth factor-driven cell cycle progression. Recent findings have emphasized a critical role of mTOR in cellular homeostasis with a crucial role in podocyte function. Beyond CD8(+) and regulatory T-cell control, mTOR protein is involved in critical biological functions of T helper cells or dendritic cells. New specific inhibitors of mTORC1/C2 are available and shed new light on mTOR functions. Finally, clinical trials have better defined the use of mTOR inhibitors and emphasized their role in cancer prevention. The mTOR pathway is considered as a key integrator of multiple inputs that drives numerous biological processes in cell biology. mTOR inhibitors are potent immunosuppressive drugs for solid organ transplantation. Newly designed specific inhibitors of mTOR complex 1 and 2 offer promising therapeutic effects and a better understanding of the pathway. Many conditions may benefit from mTOR inhibition for a short period, but tolerance of treatment in a chronic setting remains a major concern.Keywords
This publication has 107 references indexed in Scilit:
- A lysosome‐to‐nucleus signalling mechanism senses and regulates the lysosome via mTOR and TFEBThe EMBO Journal, 2012
- The tumor suppressor Tsc1 enforces quiescence of naive T cells to promote immune homeostasis and functionNature Immunology, 2011
- The kinase mTOR regulates the differentiation of helper T cells through the selective activation of signaling by mTORC1 and mTORC2Nature Immunology, 2011
- Structure of the Human mTOR Complex I and Its Implications for Rapamycin InhibitionMolecular Cell, 2010
- The Receptor SIGIRR Suppresses Th17 Cell Proliferation via Inhibition of the Interleukin-1 Receptor Pathway and mTOR Kinase ActivationImmunity, 2010
- An Emerging Role of mTOR in Lipid BiosynthesisCurrent Biology, 2009
- The mTOR Kinase Differentially Regulates Effector and Regulatory T Cell Lineage CommitmentImmunity, 2009
- Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancersNature Medicine, 2008
- Phosphatidylinositol-3-OH kinase and nutrient-sensing mTOR pathways control T lymphocyte traffickingNature Immunology, 2008
- Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitiveNature Cell Biology, 2004